Baillie Gifford & Co. Cuts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Baillie Gifford & Co. decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,789,356 shares of the biopharmaceutical company’s stock after selling 242,535 shares during the period. Alnylam Pharmaceuticals accounts for about 0.9% of Baillie Gifford & Co.’s portfolio, making the stock its 23rd biggest holding. Baillie Gifford & Co. owned approximately 2.13% of Alnylam Pharmaceuticals worth $1,271,946,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ALNY. Root Financial Partners LLC purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at approximately $25,000. Salomon & Ludwin LLC bought a new position in shares of Alnylam Pharmaceuticals during the third quarter worth $27,000. ORG Partners LLC grew its stake in Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 33 shares in the last quarter. Quent Capital LLC purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at $39,000. Finally, Hilltop National Bank bought a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $41,000. Institutional investors own 92.97% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on ALNY shares. Stifel Nicolaus raised their price objective on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. HC Wainwright set a $570.00 price target on Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, November 4th. Wall Street Zen raised Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. JPMorgan Chase & Co. lowered their target price on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research report on Monday, October 13th. Finally, Oppenheimer assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price target on the stock. Twenty-two analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $485.21.

Insider Activity at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 15,650 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $453.69, for a total value of $7,100,248.50. Following the sale, the chief executive officer directly owned 65,409 shares in the company, valued at approximately $29,675,409.21. This represents a 19.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Pushkal Garg sold 1,510 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $547,933.70. Following the sale, the executive vice president directly owned 22,511 shares of the company’s stock, valued at $8,168,566.57. This represents a 6.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 56,955 shares of company stock worth $24,072,733 in the last three months. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Stock Down 3.2%

Shares of ALNY opened at $357.98 on Friday. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. The business has a fifty day moving average of $409.91 and a 200 day moving average of $422.52. The company has a market cap of $47.29 billion, a PE ratio of 1,491.58 and a beta of 0.32. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.